The Schall Law Firm Wants Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Securities Related Infractions
| ADMA Stock | USD 15.83 0.56 3.42% |
About 61% of ADMA Biologics' investor base is looking to short. The analysis of the overall investor sentiment regarding ADMA Biologics suggests that many traders are alarmed. The current market sentiment, together with ADMA Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use ADMA Biologics stock news signals to limit their universe of possible portfolio assets.
ADMA |
LOS ANGELES, CA ACCESSWIRE November 25, 2024 The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologic
Read at accesswire.com
 |
ADMA Biologics Fundamental Analysis
We analyze ADMA Biologics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADMA Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADMA Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
ADMA Biologics is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
ADMA Biologics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ADMA Biologics stock to make a market-neutral strategy. Peer analysis of ADMA Biologics could also be used in its relative valuation, which is a method of valuing ADMA Biologics by comparing valuation metrics with similar companies.
Peers
ADMA Biologics Related Equities
| IBIO | Ibio | 9.95 | ||||
| XFOR | X4 Pharmaceuticals | 8.11 | ||||
| ATRA | Atara Biotherapeutics | 1.30 | ||||
| CRBU | Caribou Biosciences | 0.86 | ||||
| BCRX | BioCryst Pharmaceuticals | 0.81 | ||||
| PLX | Protalix Biotherapeutics | 0.86 | ||||
| MCRB | Seres Therapeutics | 1.32 | ||||
| ANTX | AN2 Therapeutics | 1.75 | ||||
| AKBA | Akebia Ther | 2.70 | ||||
| ACLX | Arcellx | 3.38 | ||||
| RCUS | Arcus Biosciences | 3.58 | ||||
| INMB | INmune Bio | 3.61 | ||||
| ETNB | 89bio | 3.79 | ||||
| ANEB | Anebulo Pharmaceuticals | 4.31 | ||||
| STOK | Stoke Therapeutics | 5.73 | ||||
| TNXP | Tonix Pharmaceuticals | 6.11 | ||||
| SANA | Sana Biotechnology | 6.90 | ||||
| CDTX | Cidara Therapeutics | 7.43 | ||||
| VXRT | Vaxart | 7.84 | ||||
| FATE | Fate Therapeutics | 8.04 | ||||
| MDGL | Madrigal Pharmaceuticals | 8.15 | ||||
| PLRX | Pliant Therapeutics | 59.88 |
Complementary Tools for ADMA Stock analysis
When running ADMA Biologics' price analysis, check to measure ADMA Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADMA Biologics is operating at the current time. Most of ADMA Biologics' value examination focuses on studying past and present price action to predict the probability of ADMA Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADMA Biologics' price. Additionally, you may evaluate how the addition of ADMA Biologics to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |